Introduction
============

Aniridia (MIM ^\#^106210) is a congenital disorder of complete or partial iris hypoplasia ([@b1-mmr-18-02-1623],[@b2-mmr-18-02-1623]). The prevalence of aniridia ranges from 1:50,000 to 1:100,000 live births ([@b3-mmr-18-02-1623]). Aniridia can occur as an isolated or a syndromic form ([@b4-mmr-18-02-1623]). Approximately two thirds of all cases are familial following an autosomal dominant mode of inheritance with high penetrance, while the remaining cases are sporadic ([@b3-mmr-18-02-1623],[@b5-mmr-18-02-1623]).

Classic aniridia is a panocular condition caused by *PAX6* heterozygous mutations and it affects the iris, cornea, lens, retina and optic nerve. It can be accompanied by foveal hypoplasia, strabismus and optic nerve hypoplasia, generally leading to impaired visual acuity, while late-onset manifestations can include nystagmus, glaucoma, cataract and corneal pannus ([@b5-mmr-18-02-1623],[@b6-mmr-18-02-1623]). Patients may also display non-ocular sensory and neurological abnormalities, such as reduced olfaction and hearing difficulties ([@b7-mmr-18-02-1623]), and a range of neuroanatomical abnormalities, including hypoplasia of the anterior commissure, the pineal glands and the optic chiasm ([@b8-mmr-18-02-1623],[@b9-mmr-18-02-1623]). *PAX6* point mutations are responsible for classic aniridia in approximately 90% of patients ([@b10-mmr-18-02-1623],[@b11-mmr-18-02-1623]). *PAX6* maps to chromosomal region 11p13 and encodes a transcription factor, which plays a crucial role in early ocular morphogenesis. It is also involved in the development of the central nervous system, gut and pancreas ([@b12-mmr-18-02-1623],[@b13-mmr-18-02-1623]). Furthermore, deletions at 11p13 involving *PAX6* or the regulatory region upstream of *PAX6* leaving its coding region intact are thought to be rare causes of classic aniridia ([@b14-mmr-18-02-1623]). A small number of patients develop aniridia as part of the WAGR syndrome (Wilms tumor, Aniridia, Genital anomalies, mental Retardation) caused by a contiguous gene deletion encompassing *PAX6* and *WT1* ([@b4-mmr-18-02-1623]). Finally, about 10% of cases display aniridia-like phenotypes that result from mutations in other genes, such as *FOXC1* and *PITX2* ([@b15-mmr-18-02-1623]--[@b17-mmr-18-02-1623]). The purpose of this study was to analyze the *PAX6* gene in a group of aniridia patients of Cypriot ancestry and describe their clinical features. We identified three previously reported *PAX6* mutations, in addition to a novel frameshift variant that was identified in one of our familial cases.

Materials and methods
=====================

### Patients

A total of 17 affected individuals from six families were evaluated with a complete ophthalmological examination and then referred to the Clinical Genetics Clinic at the Cyprus Institute of Neurology and Genetics to investigate for *PAX6* mutations. Informed consent was obtained by study participants or their guardians if they were younger than 18 year olds.

### Array-comparative genomic hybridization (CGH)

Array CGH analysis or multiplex ligation-dependent probe amplification assay (MLPA) were initially performed to investigate for whole gene deletions involving *PAX6* and/or *WT1* or deletions downstream of *PAX6*. Array-CGH was performed using the Cytochip ISCA array (version 1.0; BlueGnome, Cambridge, UK) with 180,000 oligos in a 4×180 k format. Fluorescent ratios were calculated using the Blue Fuse Multi Software (version 4.2; BlueGnome). MLPA was conducted using the SALSA probemix P219-B3 (MRC-Holland, Amsterdam, Netherlands). Fragment separation by capillary electrophoresis was performed on an ABI 3130×l genetic analyzer. MLPA analysis was performed using the Coffalyser.Net Software (version 1.4; MRC-Holland).

### Mutation screening

Genomic DNA was isolated from peripheral blood using the QIAamp DNA Blood Midi Kit (Qiagen, Inc., Valencia, CA, USA). All coding exons of *PAX6, FOXC1* and *PITX2* were amplified by PCR using primers designed with Primer3 (<http://frodo.wi.mit.edu/>) and they are available upon request. Sequencing products were analyzed by a 3130×l Genetic Analyzer (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The cDNA sequence of the most common human PAX6 transcript (NM_000280) is used for the variant nomenclature. Direct sequencing of *PITX2* and *FOXC1* was performed in patients who did not carry any *PAX6* mutations only.

Results
=======

Seventeen patients from six families were recruited for this study, including eight males and nine females. One patient was a sporadic case while the remaining were familial ones. Patients from family 1 presented with isolated bilateral aniridia. The proband of family 2 presented with bilateral aniridia, cataracts, glaucoma of the left eye, nystagmus and reduced visual acuity. She also had pseudophakia of the left eye. Fundoscopy revealed small, hypoplastic discs, macular hypoplasia, mild foveal hypoplasia and optic nerve hypoplasia. Her mother had aniridia with loss of vision in the right eye and developed retinal detachment in the left. The proband of family 3 had bilateral aniridia, nystagmus, cataracts, glaucoma and photophobia. She also had a history of osteoporosis and hypercholesterolemia. Her mother had relapsing remitting multiple sclerosis in addition to aniridia. The proband of family 4 had bilateral aniridia, atrial septal defect and thyroid nodules. Patients from family 5 exhibited bilateral aniridia and cataracts. Finally, our sporadic patient from family 6 had bilateral aniridia, nystagmus, cataracts and glaucoma. He had a history of Peters anomaly and he showed markedly abnormal anterior segment. Non-ocular abnormalities included antenatal bilateral hydronephrosis, vesicoureteric obstruction, bilateral megaureter, bipolar disorder and hypertension. His parents were thought to be distantly related. All probands were negative for deletions spanning *PAX6* and/or *WT1*, excluding WAGR syndrome.

### Sequencing results

Four different heterozygous *PAX6* mutations were identified in five out of six families with aniridia, yielding a diagnostic rate of approximately 84%. Three stop-gain mutations identified in four familial cases (p.R203\*, p.R240\* and p.R317\*) have been reported elsewhere, while the frameshift mutation c.659delA (p.E220Gfs\*23) is novel and was found to occur *de novo* in the affected father ([Fig. 1](#f1-mmr-18-02-1623){ref-type="fig"}). Mutations were located in exons 8, 9 and 11. All mutations are summarized in [Table I](#tI-mmr-18-02-1623){ref-type="table"}.

Direct sequencing of the coding exons and flanking intronic sites of *PITX2* and *FOXC1* in the proband of family 5 revealed no pathogenic mutations.

Discussion
==========

In this study, we analyzed 17 patients from six different Cypriot families with aniridia and identified five different *PAX6* pathogenic variants in five out of six probands, yielding a diagnostic rate of 84% that is comparable to other studies in other populations ([@b18-mmr-18-02-1623]--[@b21-mmr-18-02-1623]). This is the first study on *PAX6* molecular analysis in aniridia patients of Cypriot ancestry. Although, deletions spanning the 3′regulatory region of *PAX6* or the *PAX6* coding region are less common than *PAX6* mutations in aniridia patients, we have performed array-CGH or MLPA first as it was recommended by Hingorani *et al* due to the clinical importance of detecting *WT1* deletions, which requires surveillance for Wilms tumor ([@b7-mmr-18-02-1623]). None of our patients carried a deletion and therefore *PAX6* mutation screening was subsequently performed.

To date, 472 unique *PAX6* variants have been recorded in the Human *PAX6* Allelic Variant Database (<http://lsdb.hgu.mrc.ac.uk/home.php?select_db=PAX6>). Over 50% of these variants comprise frameshift or stop-gain variants resulting in a premature termination codon, which usually leads to the degradation of the truncated mRNA via nonsense-mediated decay. Therefore, these mutations result in 50% reduction in protein levels supporting haploinsufficiency as the main mechanism underlying aniridia ([@b22-mmr-18-02-1623],[@b23-mmr-18-02-1623]). All of the identified variants in our study, as well, are predicted to lead to nonsense-mediated decay. Three of the identified *PAX6* variants in our study account for 16% of patients included in the *PAX6* mutation database (<http://lsdb.hgu.mrc.ac.uk/home.php?select_db=PAX6>). The first identified mutation (p.R203\*) is currently reported in 40 patients, the second one (p.R240\*) is currently reported in 51 patients and the third one (p.R317\*) is currently reported in 41 patients. These are the most recurrent mutations found in *PAX6* in aniridia patients to date.

The PAX6 protein consists of a paired domain at the N-terminus, a homeodomain and a proline-serine-threonine rich transactivation (PST) domain at the C-terminus ([@b24-mmr-18-02-1623]--[@b26-mmr-18-02-1623]). In our study, mutations were found in exons encoding the linker domain (p.R203\* and p.E220Gfs\*23), the homeodomain (p.R240\*) and the PST domain (p.R317\*). No correlation between the location of the mutation and the associated phenotypes was observed. Even though all patients had truncating mutations, not all patients had cataract, glaucoma, nystagmus or foveal hypoplasia. In addition, the impairment of visual acuity varied between patients carrying the same *PAX6* mutation, as previously observed in other studies ([@b27-mmr-18-02-1623]). The commonest additional ocular features seen in our group of patients were nystagmus, cataracts and glaucoma.

However, no copy number variants or mutations were detected in *PAX6, FOXC1* or *PITX2* in the proband of family 6 with a sporadic form of classical aniridia. Although, classical aniridia is primarily caused by *PAX6* mutations, its phenotypic presentation may overlap with aniridia-like phenotypes. The abnormal anterior segment seen in our patient prompted us to directly sequence *FOXC1* and *PITX2*, because mutations in these genes are more commonly associated with anterior segment dysgenesis even though they can also cause isolated aniridia. *FOXC1* mutations are more commonly associated with isolated ocular, heart and/or hearing defects and *PITX2* are more commonly associated with ocular, dental and umbilical anomalies. However, both genes account for approximately 40% of cases with Axenfeld-Rieger syndrome only ([@b28-mmr-18-02-1623],[@b29-mmr-18-02-1623]). Therefore, our molecular findings confirm the genetic heterogeneity that underlies aniridia-like phenotypes as other recent reports have suggested ([@b19-mmr-18-02-1623],[@b30-mmr-18-02-1623]).

In conclusion, a high diagnostic yield (84%) was obtained in this study, which was the first one to be conducted in Cyprus for aniridia patients. We have identified a novel frameshift mutation in one of our families thus expanding the number of *PAX6* mutations that cause aniridia. Mutation screening of *PAX6* plays a crucial role in determining whether the affected individual has isolated aniridia or WAGR syndrome. The identification of a *PAX6* mutation eliminates the need for surveillance by renal ultrasound and improves genetic counseling as well as the accuracy of prognosis and recurrence risk.
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###### 

Summary of *PAX6* mutational spectrum in Cypriot families.

  Protein change   Times reported in LOVD   Exon   Protein domain   Predicted effect
  ---------------- ------------------------ ------ ---------------- ------------------
  p.R203\*         40                       8      Linker domain    NMD
  p.E220Gfs\*23    0                        8      Linker domain    NMD
  p.R240\*         51                       9      Homeodomain      NMD
  p.R317\*         41                       11     PST domain       NMD

LOVD, Leiden Open (Source) Variation Database; PST, proline-serine-threonine rich transactivation; NMD, nonsense-mediated decay.
